Abstract:OBJECTIVE:Renal safety risk is currently an important factor that hinders the development of uric acid transporter 1 (URAT1) inhibitors. This study aimed to compare the renal safety and uric acid-lowering efficacy of different URAT1 inhibitors and clarify the association between them.METHODS:A systematic review of published randomized controlled trials on URAT1 inhibitors was conducted to investigate the incidence of renal safety events. A model-based analysis was performed to predict the uric acid-lowering efficacy of representative URAT1 inhibitors.RESULTS:The overall renal safety event incidences of lesinurad, verinurad, dotinurad, SHR4640, and benzbromarone in patients with hyperuricemia were 11.2 % (142/1264), 12.0 % (34/284), 0.5 % (2/421), 2.3 % (5/213), and 1.3 % (5/393), respectively. A semi-mechanistic pharmacokinetic/pharmacodynamic model was used to establish the dose-exposure-effect relationship of lesinurad, verinurad, dotinurad, and SHR4640 with or without the combination of xanthine oxidase inhibitors (XOIs). The efficacy ranking of the intermediate dose of URAT1 inhibitors with once-daily dosing was 2 mg dotinurad > 10 mg verinurad > 5 mg SHR4640 > 400 mg lesinurad. The combination of 80 mg febuxostat and 600 mg allopurinol reduced the 24-h cumulative renal uric acid excretion by 48.4 % and 48.3 %, respectively.CONCLUSION:Uric acid-lowering efficacy is not an independent factor for the renal safety risk of different URAT1 inhibitors, and structural differences could be responsible for the difference. The adverse renal effects of URAT1 inhibitors are dose-dependent, and the combination with high doses of XOIs can significantly reduce the renal safety risk by reducing uric acid excretion by the kidneys.

Urate Transporter URAT1 Inhibitors: a Patent Review (2012 - 2015)

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)

A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications

Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout

Transport mechanism and structural pharmacology of human urate transporter URAT1

Molecular basis of the urate transporter URAT1 inhibition by gout drugs

A System for Discovering Novel Uricosurics Targeting Urate Transporter 1 Based on In Vitro and In Vivo Modeling

Virtual screening and biological evaluation of natural products as urate transporter 1 (URAT1) inhibitors

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1

Identification of N-phenyl-N-(quinolin-4-yl) Amino Carboxylic Acids As URAT1 Inhibitors with Hypouricemic Effects

Structural basis for the transport and substrate selection of human urate transporter 1

Structural Insights into the Mechanisms of Urea Permeation and Distinct Inhibition Modes of Urea Transporters

The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies

Molecular mechanisms of uric acid transport by the native human URAT1 and its inhibition by anti-gout drugs

Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia

New medications in development for the treatment of hyperuricemia of gout

Systematic Review and Model-Based Analysis to Identify Whether Renal Safety Risks of URAT1 Inhibitors Are Fully Determined by Uric Acid-Lowering Efficacies.

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities

Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents

Urea Transporters Identified As Novel Diuretic Drug Targets